Int. J. Mol. Sci. 2014, 15, 11324-11349; doi:10.3390/ijms150711324

International Journal of

Molecular Sciences ISSN 1422-0067

www.mdpi.com/journal/ijms

Review

Endothelial Dysfunction in Chronic Inflammatory Diseases

Curtis M. Steyers, III 1 and Francis J. Miller, Jr. 1,2,*

1 Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA;

E-Mail: curtis-m-steyers@uiowa.edu 2 Department of Internal Medicine, Veterans Affair Medical Center, Iowa City, IA 52242, USA

* Author to whom correspondence should be addressed; E-Mail: francis-miller@uiowa.edu;

Tel.: +1-319-384-4524; Fax: +1-319-353-5552.

Received: 9 May 2014; in revised form: 23 May 2014 / Accepted: 6 June 2014 /

Published: 25 June 2014

Abstract: Chronic inflammatory diseases are associated with accelerated atherosclerosis and

increased risk of cardiovascular diseases (CVD). As the pathogenesis of atherosclerosis is

increasingly recognized as an inflammatory process, similarities between atherosclerosis and

systemic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel diseases,

lupus, psoriasis, spondyloarthritis and others have become a topic of interest. Endothelial

dysfunction represents a key step in the initiation and maintenance of atherosclerosis and

may serve as a marker for future risk of cardiovascular events. Patients with chronic

inflammatory diseases manifest endothelial dysfunction, often early in the course of the

disease. Therefore, mechanisms linking systemic inflammatory diseases and atherosclerosis

may be best understood at the level of the endothelium. Multiple factors, including

circulating inflammatory cytokines, TNF-α (tumor necrosis factor-α), reactive oxygen

species, oxidized LDL (low density lipoprotein), autoantibodies and traditional risk factors

directly and indirectly activate endothelial cells, leading to impaired vascular relaxation,

increased leukocyte adhesion, increased endothelial permeability and generation of a

pro-thrombotic state. Pharmacologic agents directed against TNF-α-mediated inflammation

may decrease the risk of endothelial dysfunction and cardiovascular disease in these

patients. Understanding the precise mechanisms driving endothelial dysfunction in patients

with systemic inflammatory diseases may help elucidate the pathogenesis of atherosclerosis

in the general population.

OPEN ACCESS

Int. J. Mol. Sci. 2014, 15 11325

Keywords: endothelial dysfunction; endothelium; atherosclerosis; inflammation;

inflammatory disease; arthritis

1. Introduction

An expanding body of evidence demonstrates that chronic autoimmune inflammatory diseases are

associated with accelerated atherosclerosis and increased cardiovascular morbidity and mortality

compared to the general population [1,2]. Although rheumatoid arthritis has been most extensively

studied, an abundance of data now exists demonstrating excess cardiovascular risk in a multitude of other

inflammatory diseases, including systemic lupus erythematosus, the seronegative spondyloarthropathies,

psoriasis and inflammatory bowel disease [3–8].

Endothelial dysfunction has been postulated to represent an initial step in the pathogenesis of

atherosclerosis in the general population [9]. Accordingly, efforts to elucidate unique mechanisms

driving increased cardiovascular risk in patients with inflammatory diseases have often focused on the

endothelium, which serves as an interface for multiple converging risk factors. In this review, we outline

the evidence for and the significance of endothelial dysfunction in several chronic inflammatory

diseases. We review the epidemiology and potential mechanisms of endothelial dysfunction in

inflammatory diseases, highlighting shared features. Finally, we summarize the available data regarding

the efficacy of anti-inflammatory therapies in reducing endothelial dysfunction and potentially mitigating

cardiovascular risk.

We queried the PubMed database (NCBI, Bethesda, MD, USA) using the MESH searches for

relevant studies using the following search terms in various combinations: rheumatoid arthritis;

systemic lupus erythematosus; psoriasis; seronegative spondyloarthritis; inflammatory bowel

disease; endothelial function; endothelial dysfunction; endothelial activation; forearm blood flow;

flow-mediated vasodilation; cardiovascular disease (CVD); cardiovascular mortality; myocardial

infarction; inflammation. Because of the limited number of relevant studies, there were no defined

inclusion or exclusion criteria. Studies were screened informally for size and methodological quality.

Studies reviewed ranged over the period of 1982–2014, with preference given to more recent data.

Systematic reviews and meta-analyses were incorporated when available.

2. Endothelial Dysfunction: Definitions and Prognostic Implications

Through its capacity to sense and respond to mechanical and biochemical stimuli, the endothelium

plays an active and critical role in the physiologic regulation of vascular tone, cellular adhesion,

vascular smooth muscle migration and resistance to thrombosis [9,10]. Endothelial dysfunction—perhaps

more appropriately referred to as endothelial activation—refers to its failure to perform these

physiologic functions, often as a maladaptive response to pathological stimuli. The phenotypic features

of endothelial dysfunction include upregulated expression of cellular adhesion molecules, compromised

barrier function leading to increased leukocyte diapedesis, increased vascular smooth muscle tone

secondary to impaired processing of vasodilator substances such as nitric oxide and prostacyclin as well

as increased production of vasoconstrictor substances including endothelin, and reduced resistance

Int. J. Mol. Sci. 2014, 15 11326

to thrombosis [10]. These processes are thought to represent important steps in the initiation and

maintenance of atherosclerosis and have been associated with propensity towards atherothrombosis and

cardiovascular complications in advanced disease [9–11].

Endothelial dysfunction has emerged as an important surrogate endpoint for cardiovascular events.

Its role in initiating the cascade of events leading to atherosclerosis and atherothrombosis may position

it well for use as an early indicator of disease at a point that may allow for effective risk factor

modification or pharmacologic intervention prior to the development of full-blown atherosclerosis.

Furthermore, the endothelium is viewed as an integrator of vascular risk: the mechanisms by which

epidemiologically proven cardiovascular risk factors lead to atherosclerosis might be interrogated best

at the level of the endothelium, where the processing of these pathogenic signals may converge into

one or several common pathways in the genesis of advanced atherosclerosis.

3. Assessment of Endothelial Function

Endothelial function can be assessed in humans by assaying its capacity to perform its various

physiologic functions, including regulation of vasomotor tone, expression of adhesion molecules and

maintenance of an anti-thrombotic microenvironment. In contemporary clinical research, endothelial

function is typically assessed by measuring changes in vasomotor tone in response to various stimuli.

Methods of measuring vascular reactivity have become the standard largely due to their reproducibility

and demonstrated correlation with other measures of atherosclerosis. Quantification of soluble cellular

adhesion molecule expression has also been widely performed, although the usefulness of this

technique has not been well established. The most common methods are reviewed below.

3.1. Forearm Blood-Flow

Quantification of forearm blood-flow (FBF) by venous occlusion plethysmography in response to

intra-arterial infusions of vasodilator substances has been historically used to assess vascular reactivity

in various patient populations [12]. In this method, endothelial-dependent vasodilation is assayed by

intra-brachial infusion of acetylcholine (ACh), an endothelium-dependent vasodilator via induction of

endothelial nitric oxide synthase (eNOS) and prostacyclin. The vasodilator response to sodium

nitroprusside (SNP), a direct nitric oxide donor and endothelium-independent vasodilator, is also

typically assessed in this method. Pure endothelial dysfunction is characterized by impaired

vasodilation in response to ACh but intact responsiveness to SNP. FBF has been shown to correlate

closely with coronary artery ACh-induced vasodilation [13]. Although reproducible and accurate, FBF

measurement is limited by its requirement for arterial cannulation, thereby limiting its repeatability and

use in larger cohort studies.

3.2. Flow-Mediated Vasodilation

Flow-mediated vasodilation (FMD) is currently the most widely used method for assessment of

vascular reactivity due to its non-invasive nature [12–14]. This technique employs ultrasound to

measure changes in brachial artery diameter in response to shear stress-induced vasodilation, an

endothelium-dependent process. A sphygmomanometer cuff is placed on the patient’s forearm distal to the

Int. J. Mol. Sci. 2014, 15 11327

brachial artery and inflated until all flow ceases. It is then released after a pre-specified period of ischemia,

leading to reactive hyperemia secondary to distal microvessel dilation by local factors. The enhanced

brachial artery flow is associated with increased shear stress, leading to vasodilation in the presence of a

functioning endothelium. This technique has been demonstrated to be endothelium-dependent, as local

administration of N-mono-methyl-L-arginine (L-NMMA), an inhibitor of NOS, leads to marked

reduction in brachial artery dilatation [14]. Studies utilizing FMD also commonly measure brachial

artery reactivity in response to oral nitroglycerin, an endothelium-independent vasodilator. The FMD

method is often favored over FBF due to its non-invasiveness. It is a technically demanding technique,

however, and care must be taken by experienced individuals in order to reduce variability. Regardless

of the technical challenges, FMD has been demonstrated to correlate with coronary artery vasoreactivity,

markers of subclinical atherosclerosis and future cardiovascular events [13–17].

3.3. Microvascular Vasodilation

There has been some concern that assessment of conduit artery function may not accurately reflect

endothelial function in the microcirculation. Assessment of endothelium-dependent vasodilation in

the cutaneous microcirculation is typically performed by using laser Doppler imaging to measure

responses to infusion of vasodilator substances via iontophoresis [18]. Similar to assessment of the

larger vessels, ACh is used as the endothelium-dependent vasodilator while SNP is used to assess

endothelium-independent mechanisms. These substances are delivered transdermally by application of

an electrical field to induce migration of the ionized drug into cutaneous capillaries. Laser Doppler

imaging allows for measurement of microvascular perfusion. Various other techniques have been

employed to assess microvascular function in tissues other than the skin. Transthoracic echocardiography

has been used to assess coronary flow reserve and recently positron emission tomography (PET)

has been used to assess myocardial blood flow and coronary flow reserve [19]. These techniques

have not yet been widely applied to assessment of endothelial function in patients with chronic

inflammatory diseases.

3.4. Plasma Biomarkers of Endothelial Dysfunction

Efforts to define plasma biomarkers for endothelial dysfunction have largely focused on soluble

intercellular adhesion molecules (CAMs), including intercellular adhesion molecule 1 (ICAM-1),

vascular cell adhesion molecule (VCAM-1), E-selectin and others [20,21]. These molecules are

typically expressed at the surface of the endothelial cell in response to activation by inflammatory

cytokines or other stimuli and bind leukocyte-specific adhesion molecules, leading to increased

leukocyte affinity to the endothelial surface and eventually increased transendothelial migration.

Although they have been extensively studied, the prognostic value of soluble CAMs remains limited

due to poor reproducibility. There is some evidence, however, that elevated ICAM-1 and E-selectin

levels are associated with increased risk of incident clinical coronary heart disease [21].

Recently, the protein asymmetric dimethylarginine (ADMA), an endogenous eNOS inhibitor, has

garnered interest as a potential biomarker for endothelial dysfunction [22]. Plasma levels of ADMA

are negatively correlated with NO levels and are elevated in a variety of diseases traditionally

associated with cardiovascular risk, including hypertension, dyslipidemia, diabetes mellitus and

Int. J. Mol. Sci. 2014, 15 11328

chronic kidney disease [22]. Elevated plasma ADMA has also been associated with increased risk of

cardiovascular events across a range of patient populations [23]. Numerous other molecules, including

inflammatory cytokines, regulators of thrombosis and indicators of endothelial damage and repair have

been proposed as biomarkers for endothelial dysfunction [24]. The clinical significance of most of

these potential biomarkers remains unclear, however.

4. Clinical Findings of Major Chronic Inflammatory Diseases Suggest Cardiovascular Risk

Rheumatoid arthritis, systemic lupus erythematosus, the seronegative spondyloarthropathies,

psoriasis and inflammatory bowel disease have all been associated clinically with excessive

cardiovascular risk [1–8,25]. Over the last several decades, there has been considerable interest in

characterizing this excess cardiovascular risk in an attempt to identify potential risk factors and

mechanisms responsible for the genesis of atherosclerosis in these populations (Table 1).

Table 1. Relative risk of cardiovascular morbidity and mortality.

Disease CAD Risk (RR or OR) Cardiovascular Mortality (RR)

Rheumatoid Arthritis 1.5–2.0 [26,27] 1.5 [28] Systemic Lupus Erythematosus 2.2–2.6 [29,30] 1.7 [31]

Psoriasis (severe) 1.5–7.1 [7,25] 1.1–1.6 [7,25] Ankylosing Spondylitis 1.9 [32,33] 1.3–2.1 [5]

Inflammatory Bowel Disease 1.2–1.4 [6,34] 1.0 [34,35]

Abbreviations: RR: Relative risk; OR: Odds radio; CAD: Coronary artery disease.

4.1. Rheumatoid Arthritis (RA)

It has been known for many years that coronary artery disease is largely responsible for the excess

morbidity and mortality in patients with RA. Endothelial dysfunction in RA was first described in a

seminal 2002 study demonstrating impaired brachial artery responsiveness to ACh by FBF in patients

with early disease [36]. Impaired endothelium-dependent vasodilation has since been repeatedly

demonstrated at various stages of disease and across a spectrum of disease activity by several

different techniques [37–41]. Microvascular dysfunction has similarly been described in RA, and

endothelial-dependent vasodilation in the cutaneous microcirculation has been shown to correlate with

disease activity [42,43]. There has been less consistency in the correlation between disease activity

and macrovascular function, however. Whereas several studies have demonstrated impaired FMD or

FBF in patients with early RA with low disease activity [36,37,39,40], others have failed to show

differences in this population [44,45]. Discordance may be related to definitions of “early” and “low”

disease activity. A 2012 systematic review of vascular function and morphology in RA included

57 cross-sectional studies and 27 longitudinal studies [46]. The vast majority of these studies reported

that endothelium-dependent vasodilation was significantly impaired in patients with RA compared to

healthy controls. Studies addressing the correlation between endothelial function and markers of

systemic inflammation and disease activity (tender/swollen joint counts, biomarkers of systemic

inflammation) were less convincing, however. The authors concluded that the available evidence does

not wholly support a correlation between disease activity and macrovascular function [46].

Int. J. Mol. Sci. 2014, 15 11329

Efforts to characterize endothelial function by measuring soluble plasma biomarkers in patients

with rheumatoid arthritis have been largely unsuccessful. Littler et al. [47] first described an expression

profile of intercellular adhesion molecules in 22 patients with RA. While ICAM-1, ICAM-3, VCAM-1,

L-selectin and P-selectin were found to be elevated in sera of patients with RA, only P-selectin

correlated with disease activity. Others have identified unique expression profiles in RA patients [48–50],

although ICAM-1 and P-selectin were also found to be elevated in RA patients in these studies.

Several investigators have failed to demonstrate differences in adhesion molecule expression between

patients and healthy controls [51]. There is also discordance with regard to the correlation between

adhesion molecule expression and markers of disease activity. Plasma levels of ADMA have also been

found to be elevated in patients with RA. ADMA levels correlate inversely with FMD and directly

with markers of systemic inflammation [52]. In general, the clinical utility of biomarkers for

endothelial dysfunction in inflammatory diseases remains unclear. While it appears unlikely that

cellular adhesion molecules will serve as important prognostic indicators for CVD, ADMA is more

promising. Other biomarkers currently under investigation, such as circulating endothelial progenitor

cells, may prove to be useful markers of endothelial dysfunction.

4.2. Systemic Lupus Erythematosus (SLE)

The excess burden of CVD in patients with SLE is now well established. Similar to RA, endothelial

function has been widely used as a surrogate endpoint for CVD in patients with SLE. Impaired FMD

was observed in patients with SLE as early as 2002 [53]. Multiple subsequent studies have validated

this observation [54–56], including studies interrogating endothelial function in the microcirculation [57].

One study failed to demonstrate differences in FMD between SLE patients and controls, however [58].

Differences in population characteristics may account for this discordance. Importantly, all of

these studies excluded patients with known CVD. Taken together, the available evidence strongly

supports the presence of impaired endothelium-dependent vasodilation in patients with SLE without

documented CVD.

As with RA, efforts to characterize the expression profile of biomarkers for endothelial dysfunction

in patients with SLE have been less successful than vascular reactivity studies. Sfikakis demonstrated

increased levels of circulating ICAM-1 in patients with SLE [59]. Tulek and colleagues replicated

these results but failed to demonstrate a correlation between ICAM-1 levels and disease activity or

markers of systemic inflammation [60]. In contrast, Machold and colleagues failed to demonstrate

differences in ICAM-1 levels between SLE patients and healthy controls [61]. Several other groups

have attempted to correlate adhesion molecule levels with markers of disease activity. The results have

been widely variable, although at least two studies demonstrated a correlation between VCAM-1 levels

and disease activity [62–64]. Given the heterogeneity between studies and the disparate patterns of

results, it is difficult to conclude that patients with SLE exhibit a distinct profile of adhesion molecule

expression. There is some weak evidence, however, that during periods of high disease activity and

increased systemic inflammation, levels of soluble intercellular adhesion molecules tend to be elevated

in patients with SLE. The implications of these findings remain unclear.

Int. J. Mol. Sci. 2014, 15 11330

4.3. The Seronegative Spondyloarthropathies and Psoriasis

Much less is known about the cardiovascular risk associated with the seronegative

spondyloarthropathies; however, the available evidence suggests that these diseases confer increased

risk of cardiovascular morbidity and mortality [4,5]. Similarly, only a handful of authors have assessed

endothelial function in these diseases. Findings have been consistent, however. In two studies of

patients with ankylosing spondylitis and one study with psoriatic arthritis, FMD was significantly

impaired compared to healthy controls [65–67]. One study demonstrated that the reduction in FMD

correlated significantly with markers of disease activity [65].

Less is known about adhesion molecule expression in this population. As with RA and SLE, the

available data are discordant. Wendling et al. [68] demonstrated that mildly elevated ICAM-1 levels

correlated with markers of disease activity (i.e., erythrocyte sedimentation rate (ESR), C-reactive

protein (CRP), disease severity score) in patients with spondyloarthropathies. Moreover, markedly

elevated ICAM-1 levels (>400) were found only in patients with disease. In contrast, Sari and

colleagues failed to demonstrate any significant differences in ICAM, VCAM, E-selectin or P-selectin

levels in patients with spondyloarthropathies [69]. Plasma levels of ADMA also appear to be elevated

in patients with spondyloarthropathies, although attempts to correlate ADMA levels with markers of

disease activity or other markers of endothelial dysfunction have been unsuccessful [70,71].

Cutaneous psoriasis, even in the absence of joint disease, has been linked to accelerated

atherosclerosis. The evidence for this association is less robust than for RA and SLE, though the

available data support a significantly increased risk for cardiovascular events and mortality in patients

with severe disease. Patients with mild disease may be spared [7,25]. Accordingly, many groups have

sought to characterize endothelial function in patients with cutaneous psoriasis. Although results have

been mixed, a 2014 systematic review of 20 studies of endothelial function in psoriasis patients found

that FMD was significantly impaired in the majority of studies in which FMD was used [72]. Some

data suggest that the likelihood of endothelial dysfunction is correlated with disease severity or disease

duration [73]; however, a number of studies of patients with disease classified as “severe” have

demonstrated no impairment in FMD [74,75]. Interestingly, increased carotid intima-media thickness,

a measure of subclinical atherosclerosis, has been demonstrated repeatedly in patients with psoriasis

and has been shown to correlate with FMD [72,73]. Taken together, these data suggest that patients

with psoriasis display impaired endothelial-dependent relaxation and that this may correlate with

future development of atherosclerosis and cardiovascular events.

4.4. Inflammatory Bowel Disease (IBD)

Similar to psoriasis, there has been recent interest in exploring the cardiovascular implications of

inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis (UC). While individual

studies have demonstrated an increased risk of cardiovascular events in patients with IBD, mortality

risk is less clear. A 2014 meta-analysis of 9 studies demonstrated that patients with IBD were at

significantly increased risk of ischemic heart disease and stroke [6]. Mortality was not addressed.

Multiple other groups, including Dorn and colleagues in a 2007 meta-analysis of 11 studies, have

failed to demonstrate increased risk of cardiovascular mortality in patients with IBD [35]. While there

Int. J. Mol. Sci. 2014, 15 11331

is ample evidence of accelerated atherosclerosis in this population, it remains unclear why these

patients are spared from an associated mortality risk.

In 2003 Hatoum and colleagues demonstrated that the intestinal microvessels in patients with IBD

show significantly impaired endothelium-dependent vasodilation compared to vessels from healthy

control patients [76]. In addition, the microcirculation in uninvolved segments of bowel remained

unaffected, indicating that the mechanism of local endothelial dysfunction may not be related to

systemic inflammation. This led to an exploration of generalized endothelial function in patients with

IBD. Kocaman and colleagues first demonstrated that generalized endothelial dysfunction is a feature

of ulcerative colitis [77]. FMD of the brachial artery was significantly impaired in ulcerative colitis

patients, and disease severity was an important determinant of the degree of impairment. Multiple

subsequent studies have supported the observation that FMD of the brachial artery is impaired in

patients with both UC and IBD, lending credence to the hypothesis that generalized endothelial

dysfunction is a feature of IBD, not a tissue-specific phenomenon limited to the GI tract [78,79].

5. Animal Models

Multiple models of inflammatory arthritis have been described for the study of rheumatoid arthritis

and other inflammatory joint diseases in animals. The collagen-induced arthritis (CIA) model in mice

is the most widely-used animal model for the study of RA. In this model, intradermal inoculation of

mice with type II collagen and Complete Freund’s Adjuvant (CFA) generates an intense inflammatory

polyarthritis immunologically similar to RA [80]. He and colleagues recently demonstrated that CIA

mice have significantly impaired endothelium-dependent vasodilation compared to control mice [81].

In a separate study, aortic endothelium isolated from CIA mice was shown to over-express VCAM-1 [82].

Rats with a similar adjuvant-induced arthritis also exhibit both an inflammatory polyarthritis and

impaired endothelium-dependent vasodilation [83,84]. A collagen-induced arthritis model was

recently described in sheep. Sheep with inflammatory arthritis demonstrated marked impairment in

endothelium-dependent vasodilation in the coronary and digital arteries, whereas endothelium-independent

vasodilation was intact [85]. Taken together, there is convincing evidence that animal models of

inflammatory arthritis exhibit generalized endothelial dysfunction that may provide insight into the

mechanisms linking inflammatory diseases and endothelial dysfunction in humans.

6. Mechanisms of Endothelial Dysfunction

While it is clear that multiple chronic inflammatory diseases are associated with endothelial

dysfunction and cardiovascular morbidity, the mechanistic links between inflammatory diseases and

CVD have not been fully elucidated. The role of traditional cardiovascular risk factors in patients with

RA and SLE has received considerable attention, though traditional factors alone are insufficient to

explain the excess burden of CVD in these populations. It seems likely that chronic inflammation, a

shared feature of these diseases, is involved in the pathogenesis of accelerated endothelial dysfunction.

Several potential mechanisms are explored below (Figure 1).

Int. J. Mol. Sci. 2014, 15 11332

Figure 1. Mediators of endothelial dysfunction in inflammatory diseases. TNF-α (tumor

necrosis factor-α) exerts its effects on the endothelium through its receptor, TNFR. Binding

of TNFR by TNF-α leads to diminished eNOS (endothelial nitric oxide synthase) protein

expression via suppression of promoter activity and destabilization of its mRNA. TNFR

suppresses eNOS activity by preventing the degradation of its endogenous inhibitor,

ADMA (asymmetric dimethylarginine). TNFR signaling also induces the transcription

factor NF-κB leading to enhanced expression of intercellular adhesion molecules (ICAM-1:

intercellular adhesion molecule-1; VCAM-1: vascular cell adhesion molecule-1), TNF-α and

Nox1 (NADPH-oxidase-1). NF-κB induction is also mediated by oxidized low density

lipoprotein (oxLDL), reactive oxygen species (ROS) and binding of various autoantibodies

(AECA: anti-endothelial cell antibodies; APLA: antiphospholipid antibodies; anti-oxLDL:

anti-oxidized LDL antibodies). eNOS uncoupling, mediated in part by ROS, is associated

with reduced NO (nitric oxide) production and enhanced generation of ROS. eNOS activity

is also suppressed by oxLDL.

6.1. Tumor Necrosis Factor-α (TNF-α)

The vascular endothelium is known to be a target of TNF-α. On a cellular level, TNF-α induces the

expression of genes associated with inflammation, coagulation and proliferation. Decreased nitric

oxide (NO) bioavailability appears to be a common and critical step linking TNF-α to endothelial

dysfunction. Multiple groups have shown that eNOS protein expression is reduced via TNF-α- induced

Int. J. Mol. Sci. 2014, 15 11333

inhibition of eNOS promoter activity and mRNA destabilization [86,87]. NO availability is also

compromised in the presence of TNF-α secondary to impaired degradation of ADMA, an endogenous

inhibitor of NOS. Furthermore, TNF-α induces CAM expression on the surface of vascular endothelial

cells. This effect is mediated via isoform one of the TNF-receptor (TNFR1). Activation of TNFR1

leads to increased CAM expression via induction of NF-κB [87,88]. NO is also known to be an

inhibitor of CAM expression [89]. TNF-α may therefore lead to increased CAM expression by

multiple pathways.

The effect of TNF-α on NO availability and subsequent endothelial dysfunction has also been

demonstrated in vivo in both animal and human models. Intravenous delivery of TNF-α in rats leads to

impaired endothelium-dependent vasodilation [90]. Intra-arterial infusion of TNF-α in humans also

impairs local endothelium-dependent vasodilation measured by FBF [91]. Non-specific induction of an

acute systemic inflammatory response by Salmonella typhi vaccination also causes reduced FBF [92].

This effect is mediated by impaired NO bioavailability as demonstrated by rescue of vascular

reactivity with the NOS inhibitor L-NNMA (L-NG-monomethyl Arginine) [91]. The downstream

effects of TNF-α-mediated inflammation are illustrated in an apoE−/−, TNF-α−/− mouse model. Mice

deficient in TNF-α develop less atherosclerosis than those with intact TNF-α expression (i.e., apoE−/−

single knockout) [93]. This is associated with decreased expression of ICAM-1, VCAM-1 and

monocyte chemotactic protein-1 (MCP-1).

It is well known that TNF-α plays a critical role in the inflammation associated with RA, SLE, IBD,

psoriasis and spondyloarthritis. This common feature is illustrated by the efficacy of anti-TNF-α

agents in many of these diseases. Given the central role of TNF-α in the pathogenesis of many chronic

inflammatory diseases and its well-characterized effects on the endothelium as described above, it is

reasonable to conclude that increased circulating TNF-α is implicated in the induction of endothelial

dysfunction and initiation of atherosclerosis in these diseases (Figure 2). This hypothesis is supported

by the beneficial effects of anti-TNF-α agents on endothelial function in patients with chronic

inflammatory diseases, as discussed later.

6.2. Oxidative Stress

Chronic inflammatory diseases are generally associated with increased oxidative stress. In RA,

reactive oxygen species (ROS) levels from peripheral blood neutrophils correlate positively with

disease severity and markers of systemic inflammation [94]. Inflammatory cytokines, including

TNF-α, are largely responsible for the increased ROS production in these diseases. TNF-α increases

activity of the NADPH oxidases (NOX), which catalyze the transfer of electrons onto molecular

oxygen to generate superoxide by neutrophils and endothelial cells [87,95]. As discussed previously,

the bioavailability of NO is a critical factor in determining vascular reactivity. In addition to its

production by NOS and metabolism by ADMA, NO bioavailability is also modulated by ROS.

Superoxide rapidly reacts with NO to produce peroxynitrite, thereby decreasing NO availability [96].

The importance of this mechanism is demonstrated by observations that eNOS is paradoxically

up-regulated in hypertension and diabetes mellitus, conditions associated with endothelial dysfunction [96].

ROS also contribute to the “uncoupling” of eNOS, leading to enhanced superoxide generation and

decreased NO production [97]. Multiple in vivo animal models have demonstrated reduced NO

Int. J. Mol. Sci. 2014, 15 11334

bioavailability in the presence of elevated ROS, and reversal of endothelial dysfunction has been

achieved via infusion of antioxidants [98].

In addition to downregulating NO bioavailability, superoxide and other ROS are capable of

inducing NF-κB, a critical step in transforming endothelial cells into an “activated” state characterized

in part by increased surface expression of CAMs [94,99]. As discussed previously, CAM expression

by endothelial cells represents a fundamental feature of endothelial dysfunction, leading to enhanced

leukocyte affinity and eventually migration into the subendothelial space, key steps in the initiation

and maintenance of atherosclerosis. Activation of NF-κB can also stimulate NOX expression, further

enhancing ROS production in the endothelium and regenerating the destructive loop of inflammation

and oxidative stress [100].

Figure 2. From local inflammation to systemic endothelial dysfunction. TNF and

inflammatory cytokines spread from the primary, disease-specific site of local

inflammation into the systemic circulation to propagate a systemic inflammatory response.

The byproducts of systemic inflammation, including reactive oxygen species (ROS), lipid

abnormalities and other metabolic derangements are dependent on peripheral tissues such

as the liver and adipose. These mediators elicit independent and complementary effects on

the endothelium, leading to a state of endothelial dysfunction characterized by increased

adhesion molecule expression (VCAM, ICAM), leukocyte diapedesis, ROS production and

decreased NO (nitric oxide)-mediated smooth muscle relaxation and vascular dilation.

Autoantibodies are generated in a disease-specific manner and induce similar changes in

endothelial function.

Int. J. Mol. Sci. 2014, 15 11335

6.3. Dyslipidemia

The role of traditional cardiovascular risk factors such as dyslipidemia and insulin resistance in the

pathogenesis of endothelial dysfunction and atherosclerosis in patients with chronic inflammatory

diseases has received significant attention. Although it has been reported that patients with RA and

other rheumatic diseases are more likely to have elevated low-density lipoprotein (LDL) and total

cholesterol and reduced high-density lipoprotein (HDL) levels, the data are inconsistent. For example,

multiple studies have shown no differences in lipid profiles of patients with RA versus healthy

controls, whereas others have described a distinct profile of suppressed LDL and HDL in RA patients

with more advanced disease (i.e., rheumatoid cachexia) [101]. Chronic inflammation structurally alters

lipoproteins in ways that are not reflected in standard lipid profiles, however. Inflammation has been

shown to modify LDL into small, dense particles that are known to be pro-atherogenic. Indeed, RA

patients have elevated plasma levels of small, dense LDL particles [102]. TNF-α also enhances the

oxidative modification of LDL by increasing ROS production. In addition, HDL is modified by

inflammation. Small HDL particles, known to play a critical role in reverse-cholesterol transport, have

been shown to be decreased in patients with RA. The mechanisms by which small HDL is regulated

have been extensively reviewed elsewhere [101].

Dyslipidemia is independently associated with endothelial dysfunction. Elevated LDL and total

cholesterol are associated with impaired endothelium-dependent vasodilation, whereas elevated

HDL levels correlate with improved endothelial function [103]. Impaired endothelial function in

dyslipidemic patients may be caused by reduced NO availability. In dyslipidemic patients, NO

availability may be impaired by oxidized LDL-mediated reduction in NOS activity or by enhanced

metabolism of NO by ADMA [104]. Lipoproteins are also implicated in ROS production via

modulation of NOX activity and by contributing to the “uncoupling” of eNOS [105]. In addition to

modulation of NO and ROS production, oxidized LDL induces upregulation of CAM expression at the

endothelial surface and secretion of TNF-α via induction of NF-kB. These mechanisms are reviewed

elsewhere, and additional mechanisms of LDL-mediated endothelial dysfunction have been described

in various models [105].

6.4. Autoantibodies

Many chronic inflammatory diseases are associated with production of autoantibodies, many of

which are instrumental in the pathogenesis of the disease. Similarly, autoantibodies directed against

normal endothelial or plasma constituents have been detected and implicated in the pathogenesis of

endothelial dysfunction and atherosclerosis in the general population. Anti-endothelial cell antibodies

(AECA) directed against a variety of endothelial cell structural proteins have been identified in a

number of autoimmune diseases, including SLE [106]. These antibodies have been implicated in the

pathogenesis of lupus-associated vasculitis and induce endothelial dysfunction via induction of NF-kB,

leading to upregulation of CAMs and inflammatory cytokines [107]. Although these antibodies

have been described in SLE and vasculitis, their roles, if any, in the genesis of systemic endothelial

dysfunction in SLE and other inflammatory diseases, remain unclear.

Int. J. Mol. Sci. 2014, 15 11336

Antibodies directed against oxidized LDL (anti-oxLDL) have been described in patients with and

without chronic inflammatory diseases. In SLE, anti-oxLDL antibodies correlate with disease activity

and markers of systemic inflammation [108]. Although anti-oxLDL antibodies have been correlated

with markers of atherosclerosis in various models, their impact on endothelial cell function remains to

be elucidated. There is some evidence that anti-phospholipid antibodies may exhibit cross-reactivity

with oxLDL [106]. This would provide a viable mechanism for induction of endothelial dysfunction in

patients with SLE and antiphospholipid antibodies.

Antiphospholipid antibodies (aPLs) are present in the serum of nearly one third of lupus patients.

The antiphospholipid antibody syndrome (APS) is characterized by recurrent venous or arterial

thrombosis, pregnancy loss and the presence of antiphospholipid antibodies (i.e., lupus anticoagulant,

anticardiolipin antibody, and anti-B2GPI antibody). Although their contribution to venous and arterial

thrombotic events is well known, the relative contribution of aPL to the development of endothelial

dysfunction in humans, if any, is currently unclear. The effect of aPL on endothelium-dependent

vasodilatation may be reflected in the observation that patients with aPL exhibit impaired FMD and

reduced NO bioavailability versus healthy controls [109]. aPL have also been shown to enhance CAM

expression at the endothelial surface in vitro and in vivo. Efforts to measure circulating levels of

soluble adhesion molecules in patient with APS have been less consistent, however [106]. Further

studies are required to clarify whether aPL are responsible for inducing endothelial dysfunction and

atherosclerosis in the absence of other complicating risk factors.

7. Effects of Pharmacologic Interventions on Endothelial Function

7.1. Anti-Inflammatory Therapy

Methotrexate remains the mainstay of therapy for RA and several other rheumatic diseases (Table 2).

An inhibitor of folic acid metabolism, methotrexate sharply reduces systemic inflammation and

dramatically improves synovitis in patients with inflammatory arthritis. Methotrexate also appears to

improve endothelium-dependent vasodilation in patients with RA, although the data are limited [2,110].

Inhibitors of TNF-α have been employed with increasing frequency for patients with a variety of

inflammatory diseases, including RA, spondyloarthritis, IBD and psoriasis.

The critical role of TNF-α in the generation of severe systemic inflammation in these conditions

likely explains the effectiveness of these agents. TNF-α may also be largely responsible for the

endothelial dysfunction and accelerated atherosclerosis in these patients, making anti-TNF-α agents

attractive therapeutic options for preventing CVD in this population. Numerous studies have

demonstrated improved endothelium-dependent vasodilation in patients with RA after initiation of

anti-TNF-α therapy. This has been demonstrated in a vessel-specific manner by measuring FBF

immediately after intra-brachial infusion of infliximab. In this model Cardillo and colleagues

demonstrated that the local effect of infliximab on the brachial artery improved brachial artery

endothelial function without altering markers of systemic inflammation [111]. Multiple other studies

have demonstrated that anti-TNF-α agents improve FMD in RA patients who are refractory to

conventional disease modifying anti-rheumatic drugs (DMARD) therapy [112–117]. Anti-TNF-α

agents also improve endothelium-dependent vasodilation in patients with spondyloarthritis [118,119],

Int. J. Mol. Sci. 2014, 15 11337

cutaneous psoriasis [72,120] and IBD [121], although studies are small and few. Improvement in

endothelial function with anti-TNF-α therapy may correlate with improvement in disease activity and

markers of systemic inflammation [122]. The duration of the response has been controversial,

however. Several studies in RA have shown that anti-TNF-α agents induce a rapid improvement in

FMD that is lost after a period of weeks despite effective control of disease activity and systemic

inflammation [114,116]. Other studies have demonstrated sustained improvements in endothelial

function [115,123]. Factors contributing to differences in duration of response remain unclear.

Table 2. Medication and Effect on Endothelial Function.

Medication Disease(s) Target Effect on Endothelial

Function

Methotrexate RA, SpA, Psoriasis Folic acid metabolism, lymphocyte

proliferation, inflammation Likely beneficial [2,110]

Anti-TNF-α agents

RA, SpA, Psoriasis, IBD

TNF-α-mediated inflammation Strong evidence for

benefit [72,112–119,121]

Corticosteroids RA, SpA, IBD, SLE Spectrum of immune and inflammatory responses

Inconclusive [124,125]

Statins RA, SLE, traditional

CVD risk factors LDL, eNOS, pleiotropic effects on

inflammation Strong evidence for benefit [126–129]

Abbreviations: RA: rheumatoid arthritis; SpA: spondyloarthritis; IBD: inflammatory bowel disease;

SLE: systemic lupus erythematosus; CVD: cardiovascular disease; eNOS: endothelial nitric oxide synthase;

LDL: low density lipoprotein.

Anti-TNF-α agents have also been shown to reduce levels of plasma biomarkers of endothelial

dysfunction, although results have been inconsistent. Klimiuk et al. [130] demonstrated that etanercept

administration reduced levels of soluble ICAM-1, VCAM-1 and E-selectin in patients with RA.

Gonzalez-Gay and colleagues found reductions only in soluble ICAM-3 and P-selectin after infliximab

infusions for patients with RA [131]. Adalimumab therapy in patients with psoriasis has been shown to

reduce ICAM-1 levels without affecting other CAMs [120]. These findings are similar to results from

studies examining levels of CAMs at baseline across various inflammatory diseases: it has been

difficult to discern a consistent profile of CAM expression prior to or in response to disease-modifying

therapy. Although CAM expression may be a general marker for systemic inflammation and endothelial

dysfunction, its utility in clinical and translational research may be limited.

Corticosteroids have long been used to manage a variety of inflammatory diseases, but their effects

on CVD have been controversial. The association between steroids and insulin resistance and obesity

has raised concern for increased cardiovascular risk, while their anti-inflammatory effects might

mitigate this risk. Studies addressing the association between long-term steroid use in RA and CVD

have yielded variable results. A 2011 systematic review of studies of low-dose steroid use in RA found

that corticosteroids are generally associated with mildly increased cardiovascular risk [132]. Studies

did not reveal an effect of steroids on markers of subclinical atherosclerosis and endothelial function,

however. Other observational studies have demonstrated an association between corticosteroid use and

lower rates of subclinical atherosclerosis compared to patients not using steroids [133]. Veselinovic

and colleagues demonstrated that FMD is higher in RA patients treated with corticosteroids versus no

Int. J. Mol. Sci. 2014, 15 11338

therapy [124]. This study conflicts with a randomized prospective study, by Hafstrom, showing that

addition of steroids to DMARD therapy does not improve endothelial function in RA patients [125].

These results highlight the difficulty of studying the effects of single-agent steroid therapy on patients

with inflammatory disease in the modern era. Measuring the added benefit of steroids in the context of

background immune-suppressing therapy is unlikely to reveal significant improvements, even if

corticosteroids may have this effect in isolation.

7.2. Hydroxymethylglutaryl-CoA Reductase Inhibitors (Statins)

Statins exhibit pleiotropic properties influencing the vasculature that are thought to contribute to

their clinical benefit beyond the lipid-lowering effect. Although the mechanisms are incompletely

characterized, statins have been shown to improve endothelial dysfunction in patients with traditional

cardiovascular risk factors. Potential mechanisms include upregulation of eNOS, leading to enhanced

bioavailability of NO and improved vasoreactivity [132]. The use of statins as disease modifying

agents and as primary prevention for CVD in patients with chronic inflammatory diseases has also

received interest. Statin therapy has been shown to reduce disease severity in patients with RA and has

gained attention for use as a disease-modifying agent in other inflammatory diseases [124,125,133–135].

Statins have been also been shown to improve endothelium-dependent vasodilation in patients with

RA and SLE [126,134,136,137]. This effect appears to correlate positively with measures of systemic

inflammation and disease severity [137]. There is current interest in studying the long-term effects of

statin therapy on hard cardiovascular endpoints. The Trial of Atorvastatin in Rheumatoid Arthritis was

the first randomized controlled trial designed to study the effects of statin therapy in RA patients [136].

At 6 months, statins significantly improved several markers of disease severity and markers of

systemic inflammation compared to placebo. Endothelial function was not assessed, however, and the

duration of follow-up was not long enough to detect changes in cardiovascular endpoints. Only two

studies to date have addressed the effect of statins on cardiovascular events. Sheng and colleagues

conducted a population-based cohort study designed to evaluate the effects of statins on lipid levels,

cardiovascular events and all-cause mortality in RA and osteoarthritis (OA) patients [138]. Statins

similarly reduced lipid levels and were protective of cardiovascular events and mortality in RA and

OA patients without prior CVD. There was no protective effect in the secondary prevention setting for

either cohort, however. Semb et al. [139] demonstrated that statins had a similar effect on

cardiovascular events in RA and non-RA patients when used for secondary prevention. Unfortunately,

there are no randomized controlled trials addressing the effect of statin therapy on patients with RA.

8. Conclusions

Patients with chronic inflammatory diseases are at high risk for cardiovascular morbidity and

mortality. In many inflammatory diseases, this heightened risk of CVD is reflected in early endothelial

dysfunction as assessed by vasoreactivity studies, even in the absence of detectable atherosclerosis.

The endothelium therefore represents an integrator of vascular risk and the study of its dysfunction

may help elucidate mechanisms driving accelerated atherosclerosis in these populations.

There is strong evidence that the mechanisms responsible for accelerated atherosclerosis in patients

with inflammatory diseases are related to the high-grade inflammation inherent to the primary disease

Int. J. Mol. Sci. 2014, 15 11339

process. The effects of TNF-α and inflammatory cytokines on induction of endothelial dysfunction are

well described and are likely to represent key mediators of endothelial dysfunction and atherosclerosis.

Furthermore, the numerous studies demonstrating improved endothelial function after anti-TNF-α

therapy highlight the importance of these molecules in the pathogenesis of endothelial dysfunction

and may lead the way toward advances in pharmacologic prevention of CVD in these populations.

Many other mechanisms, including autoantibodies, oxidative stress and interactions with traditional

risk factors such as dyslipidemia and insulin resistance are likely to be involved, and further research is

required to elucidate the relative importance of these processes. Finally, current strategies to reduce

cardiovascular morbidity and mortality are focused on controlling traditional modifiable cardiovascular

risk factors and reducing disease activity. The precise mechanisms driving atherosclerosis are likely to

vary between different inflammatory diseases, however, and parsing out these subtleties may help

identify unique therapeutic targets for each disease.

Acknowledgments

This work was supported by the Office of Research and Development, Department of Veterans

Affairs 1BX001729 to F.J.M. and the American Heart Association GRNT12060205 to F.J.M. The

funding sources had no role in study design; in the collection, analysis and interpretation of data; in the

writing of the report; and in the decision to submit the article for publication.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Murdaca, G.; Colombo, B.M.; Cagnati, P.; Gulli, R.; Spano, F.; Puppo, F. Endothelial

dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012, 224, 309–317.

2. Prati, C.; Demougeot, C.; Guillot, X.; Godfrin-Valnet, M.; Wendling, D. Endothelial dysfunction

in joint disease. Jt. Bone Spine 2014, doi:10.1016/j.jbspin.2014.01.014.

3. Nikpour, M.; Gladman, D.D.; Urowitz, M.B. Premature coronary heart disease in systemic lupus

erythematosus: What risk factors do we understand? Lupus 2013, 22, 1243–1250.

4. Peters, M.J.; van der Horst-Bruinsma, I.E.; Dijkmans, B.A.; Nurmohamed, M.T. Cardiovascular

risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic

arthritis. Semin. Arthritis Rheum. 2004, 34, 585–592.

5. Mathieu, S.; Motreff, P.; Soubrier, M. Spondyloarthropathies: an independent cardiovascular risk

factor? Jt. Bone Spine 2010, 77, 542–545.

6. Singh, S.; Singh, H.; Loftus, E.V., Jr.; Pardi, D.S. Risk of cerebrovascular accidents and

ischemic heart disease in patients with inflammatory bowel disease: A systematic review and

meta-analysis. Clin. Gastroenterol. Hepatol. 2014, 12, 382–393 e381.

7. Gelfand, J.M.; Neimann, A.L.; Shin, D.B.; Wang, X.; Margolis, D.J.; Troxel, A.B. Risk of

myocardial infarction in patients with psoriasis. JAMA 2006, 296, 1735–1741.

Int. J. Mol. Sci. 2014, 15 11340

8. Rosner, S.; Ginzler, E.M.; Diamond, H.S.; Weiner, M.; Schlesinger, M.; Fries, J.F.; Wasner, C.;

Medsger, T.A., Jr.; Ziegler, G.; Klippel, J.H.; et al. A multicenter study of outcome in systemic

lupus erythematosus. II. Causes of death. Arthritis Rheum. 1982, 25, 612–617.

9. Davignon, J.; Ganz, P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109,

III27–III32.

10. Bonetti, P.O. Endothelial Dysfunction: A Marker of Atherosclerotic Risk. Arterioscler Thromb

Vasc Biol 2002, 23, 168–175.

11. Ross, R. Atherosclerosis--an inflammatory disease. N. Engl. J. Med. 1999, 340, 115–126.

12. Lind, L.; Hall, J.; Larsson, A.; Annuk, M.; Fellstrom, B.; Lithell, H. Evaluation of

endothelium-dependent vasodilation in the human peripheral circulation. Clin. Physiol. 2000, 20,

440–448.

13. Deanfield, J.E.; Halcox, J.P.; Rabelink, T.J. Endothelial function and dysfunction: Testing and

clinical relevance. Circulation 2007, 115, 1285–1295.

14. Ghiadoni, L.; Salvetti, M.; Muiesan, M.L.; Taddei, S. Evaluation of endothelial function by

flow mediated dilation: Methodological issues and clinical importance. High Blood Press

Cardiovasc. Prev. 2014, in press.

15. Anderson, T.J.; Uehata, A.; Gerhard, M.D.; Meredith, I.T.; Knab, S.; Delagrange, D.;

Lieberman, E.H.; Ganz, P.; Creager, M.A.; Yeung, A.C.; et al. Close relation of endothelial

function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 1995, 26,

1235–1241.

16. Widlansky, M.E.; Gokce, N.; Keaney, J.F.; Vita, J.A. The clinical implications of endothelial

dysfunction. J. Am. Coll. Cardiol. 2003, 42, 1149–1160.

17. Inaba, Y.; Chen, J.A.; Bergmann, S.R. Prediction of future cardiovascular outcomes by

flow-mediated vasodilatation of brachial artery: A meta-analysis. Int. J. Cardiovasc. Imaging

2010, 26, 631–640.

18. Roustit, M.; Cracowski, J.L. Non-invasive assessment of skin microvascular function in humans:

An insight into methods. Microcirculation 2012, 19, 47–64.

19. Recio-Mayoral, A.; Mason, J.C.; Kaski, J.C.; Rubens, M.B.; Harari, O.A.; Camici, P.G. Chronic

inflammation and coronary microvascular dysfunction in patients without risk factors for

coronary artery disease. Eur. Heart J. 2009, 30, 1837–1843.

20. Ridker, P.M.; Hennekens, C.H.; Roitman-Johnson, B.; Stampfer, M.J.; Allen, J. Plasma

concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial

infarction in apparently healthy men. Lancet 1998, 351, 88–92.

21. Hwang, S.J.; Ballantyne, C.M.; Sharrett, A.R.; Smith, L.C.; Davis, C.E.; Gotto, A.M., Jr.;

Boerwinkle, E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid

atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In

Communities (ARIC) study. Circulation 1997, 96, 4219–4225.

22. Sibal, L.; Agarwal, S.C.; Home, P.D.; Boger, R.H. The role of asymmetric dimethylarginine

(ADMA) in endothelial dysfunction and cardiovascular disease. Curr. Cardiol. Rev. 2010, 6,

82–90.

Int. J. Mol. Sci. 2014, 15 11341

23. Boger, R.H.; Maas, R.; Schulze, F.; Schwedhelm, E. Asymmetric dimethylarginine (ADMA) as a

prospective marker of cardiovascular disease and mortality--an update on patient populations

with a wide range of cardiovascular risk. Pharmacol. Res. 2009, 60, 481–487.

24. Hill, J.M.; Zalos, G.; Halcox, J.P.; Schenke, W.H.; Waclawiw, M.A.; Quyyumi, A.A.; Finkel, T.

Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl.

J. Med. 2003, 348, 593–600.

25. Samarasekera, E.J.; Neilson, J.M.; Warren, R.B.; Parnham, J.; Smith, C.H. Incidence of

cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis.

J. Investig. Dermatol. 2013, 133, 2340–2346.

26. Crowson, C.S.; Liao, K.P.; Davis, J.M., 3rd; Solomon, D.H.; Matteson, E.L.; Knutson, K.L.;

Hlatky, M.A.; Gabriel, S.E. Rheumatoid arthritis and cardiovascular disease. Am. Heart J. 2013,

166, 622–628 e621.

27. Solomon, D.H.; Goodson, N.J.; Katz, J.N.; Weinblatt, M.E.; Avorn, J.; Setoguchi, S.; Canning, C.;

Schneeweiss, S. Patterns of cardiovascular risk in rheumatoid arthritis. Ann. Rheum. Dis. 2006,

65, 1608–1612.

28. Avina-Zubieta, J.A.; Choi, H.K.; Sadatsafavi, M.; Etminan, M.; Esdaile, J.M.; Lacaille, D. Risk

of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of

observational studies. Arthritis Rheum. 2008, 59, 1690–1697.

29. Hak, A.E.; Karlson, E.W.; Feskanich, D.; Stampfer, M.J.; Costenbader, K.H. Systemic lupus

erythematosus and the risk of cardiovascular disease: results from the nurses’ health study.

Arthritis Rheum. 2009, 61, 1396–1402.

30. Magder, L.S.; Petri, M. Incidence of and risk factors for adverse cardiovascular events among

patients with systemic lupus erythematosus. Am. J. Epidemiol. 2012, 176, 708–719.

31. Bernatsky, S.; Boivin, J.F.; Joseph, L.; Manzi, S.; Ginzler, E.; Gladman, D.D.; Urowitz, M.;

Fortin, P.R.; Petri, M.; Barr, S.; et al. Mortality in systemic lupus erythematosus. Arthritis Rheum.

2006, 54, 2550–2557.

32. Mathieu, S.; Gossec, L.; Dougados, M.; Soubrier, M. Cardiovascular profile in ankylosing

spondylitis: A systematic review and meta-analysis. Arthritis Care Res. (Hoboken) 2011, 63,

557–563.

33. Peters, M.J.; Visman, I.; Nielen, M.M.; van Dillen, N.; Verheij, R.A.; van der Horst-Bruinsma, I.E.;

Dijkmans, B.A.; Nurmohamed, M.T. Ankylosing spondylitis: A risk factor for myocardial

infarction? Ann. Rheum. Dis. 2010, 69, 579–581.

34. Fumery, M.; Xiaocang, C.; Dauchet, L.; Gower-Rousseau, C.; Peyrin-Biroulet, L.; Colombel, J.F.

Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A

meta-analysis of observational studies. J. Crohns Colitis 2014, 8, 469–479.

35. Dorn, S.D.; Sandler, R.S. Inflammatory bowel disease is not a risk factor for cardiovascular

disease mortality: Results from a systematic review and meta-analysis. Am. J. Gastroenterol.

2007, 102, 662–667.

36. Bergholm, R. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid

arthritis. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1637–1641.

Int. J. Mol. Sci. 2014, 15 11342

37. Chatterjee Adhikari, M.; Guin, A.; Chakraborty, S.; Sinhamahapatra, P.; Ghosh, A. Subclinical

atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as

evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation:

An observational study. Semin. Arthritis Rheum. 2012, 41, 669–675.

38. Kerekes, G.; Szekanecz, Z.; Der, H.; Sandor, Z.; Lakos, G.; Muszbek, L.; Csipo, I.; Sipka, S.;

Seres, I.; Paragh, G.; et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis:

A multiparametric analysis using imaging techniques and laboratory markers of inflammation

and autoimmunity. J. Rheumatol. 2008, 35, 398–406.

39. Vaudo, G. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease

activity. Ann. Rheum. Dis. 2004, 63, 31–35.

40. Hänsel, S.; Lässig, G.; Pistrosch, F.; Passauer, J. Endothelial dysfunction in young patients with

long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003, 170, 177–180.

41. Syngle, A.; Vohra, K.; Kaur, L.; Sharma, S. Effect of spironolactone on endothelial dysfunction

in rheumatoid arthritis. Scand. J. Rheumatol. 2009, 38, 15–22.

42. Datta, D.; Ferrell, W.R.; Sturrock, R.D.; Jadhav, S.T.; Sattar, N. Inflammatory suppression

rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 2007, 192,

391–395.

43. Galarraga, B.; Khan, F.; Kumar, P.; Pullar, T.; Belch, J.J. C-reactive protein: The underlying

cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford) 2008, 47,

1780–1784.

44. Sodergren, A.; Karp, K.; Boman, K.; Eriksson, C.; Lundstrom, E.; Smedby, T.; Soderlund, L.;

Rantapaa-Dahlqvist, S.; Wallberg-Jonsson, S. Atherosclerosis in early rheumatoid arthritis: very

early endothelial activation and rapid progression of intima media thickness. Arthritis Res. Ther.

2010, 12, R158.

45. Foster, W.; Lip, G.Y.; Raza, K.; Carruthers, D.; Blann, A.D. An observational study of

endothelial function in early arthritis. Eur. J. Clin. Investig. 2012, 42, 510–516.

46. Sandoo, A.; Veldhuijzen van Zanten, J.J.; Metsios, G.S.; Carroll, D.; Kitas, G.D. Vascular

function and morphology in rheumatoid arthritis: A systematic review. Rheumatology (Oxford)

2011, 50, 2125–2139.

47. Littler, A.J.; Buckley, C.D.; Wordsworth, P.; Collins, I.; Martinson, J.; Simmons, D.L. A distinct

profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin

and P-selectin) in rheumatoid arthritis. Br. J. Rheumatol. 1997, 36, 164–169.

48. Klimiuk, P.A.; Fiedorczyk, M.; Sierakowski, S.; Chwiecko, J. Soluble cell adhesion

molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis.

Scand. J. Rheumatol. 2007, 36, 345–350.

49. Dessein, P.H.; Joffe, B.I.; Singh, S. Biomarkers of endothelial dysfunction, cardiovascular risk

factors and atherosclerosis in rheumatoid arthritis. Arthritis Res. Ther. 2005, 7, R634–R643.

50. Veale, D.J.; Maple, C.; Kirk, G.; McLaren, M.; Belch, J.J. Soluble cell adhesion

molecules—P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for

active rheumatoid arthritis. Scand. J. Rheumatol. 1998, 27, 296–299.

Int. J. Mol. Sci. 2014, 15 11343

51. Meyer, M.F.; Schmidt, O.; Hellmich, B.; Schatz, H.; Klein, H.H.; Braun, J. Microvascular

dysfunction in rheumatoid arthritis assessed by laser Doppler anemometry: Relationship to

soluble adhesion molecules and extraarticular manifestations. Rheumatol. Int. 2007, 28, 145–152.

52. Antoniades, C.; Demosthenous, M.; Tousoulis, D.; Antonopoulos, A.S.; Vlachopoulos, C.;

Toutouza, M.; Marinou, K.; Bakogiannis, C.; Mavragani, K.; Lazaros, G.; et al. Role of

asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human

atherosclerosis. Hypertension 2011, 58, 93–98.

53. Lima, D.S.; Sato, E.I.; Lima, V.C.; Miranda, F., Jr.; Hatta, F.H. Brachial endothelial function is

impaired in patients with systemic lupus erythematosus. J. Rheumatol. 2002, 29, 292–297.

54. Kiss, E.; Soltesz, P.; Der, H.; Kocsis, Z.; Tarr, T.; Bhattoa, H.; Shoenfeld, Y.; Szegedi, G.

Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus

patients. J. Autoimmun. 2006, 27, 211–217.

55. El-Magadmi, M.; Bodill, H.; Ahmad, Y.; Durrington, P.N.; Mackness, M.; Walker, M.;

Bernstein, R.M.; Bruce, I.N. Systemic lupus erythematosus: An independent risk factor for

endothelial dysfunction in women. Circulation 2004, 110, 399–404.

56. Piper, M.K.; Raza, K.; Nuttall, S.L.; Stevens, R.; Toescu, V.; Heaton, S.; Gardner-Medwin, J.;

Hiller, L.; Martin, U.; Townend, J.; et al. Impaired endothelial function in systemic lupus

erythematosus. Lupus 2007, 16, 84–88.

57. Wright, S.A.; O’Prey, F.M.; Rea, D.J.; Plumb, R.D.; Gamble, A.J.; Leahey, W.J.; Devine, A.B.;

McGivern, R.C.; Johnston, D.G.; Finch, M.B.; et al. Microcirculatory hemodynamics and

endothelial dysfunction in systemic lupus erythematosus. Arterioscler. Thromb. Vasc. Biol. 2006,

26, 2281–2287.

58. Svenungsson, E.; Cederholm, A.; Jensen-Urstad, K.; Fei, G.Z.; de Faire, U.; Frostegard, J.

Endothelial function and markers of endothelial activation in relation to cardiovascular disease in

systemic lupus erythematosus. Scand. J. Rheumatol. 2008, 37, 352–359.

59. Sfikakis, P.P.; Charalambopoulos, D.; Vayiopoulos, G.; Oglesby, R.; Sfikakis, P.; Tsokos, G.C.

Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus

erythematosus. Clin. Exp. Rheumatol. 1994, 12, 5–9.

60. Tulek, N.; Aydintug, O.; Ozoran, K.; Tutkak, H.; Duzgun, N.; Duman, M.; Tokgoz, G. Soluble

intercellular adhesion molecule-1 (sICAM-1) in patients with systemic lupus erythematosus.

Clin. Rheumatol. 1996, 15, 47–50.

61. Machold, K.P.; Kiener, H.P.; Graninger, W.; Graninger, W.B. Soluble intercellular adhesion

molecule-1 (sICAM-1) in patients with rheumatoid arthritis and systemic lupus erythematosus.

Clin. Immunol. Immunopathol. 1993, 68, 74–78.

62. Janssen, B.A.; Luqmani, R.A.; Gordon, C.; Hemingway, I.H.; Bacon, P.A.; Gearing, A.J.;

Emery, P. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease

activity in systemic lupus erythematosus and vasculitis. Br. J. Rheumatol. 1994, 33, 1112–1116.

63. Spronk, P.E.; Bootsma, H.; Huitema, M.G.; Limburg, P.C.; Kallenberg, C.G. Levels of soluble

VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with

systemic lupus erythematosus (SLE); a long term prospective study. Clin. Exp. Immunol. 1994,

97, 439–444.

Int. J. Mol. Sci. 2014, 15 11344

64. Sari, R.; Taysi, S.; Erdem, F.; Yilmaz, Ö.; Keleş, S.; Kiziltunç, A.; Odabaş, A.; Çetinkaya, R.

Correlation of serum levels of soluble intercellular adhesion molecule-1 with disease activity in

systemic lupus erythematosus. Rheumatol. Int. 2001, 21, 149–152.

65. Sari, I.; Okan, T.; Akar, S.; Cece, H.; Altay, C.; Secil, M.; Birlik, M.; Onen, F.; Akkoc, N.

Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford)

2006, 45, 283–286.

66. Gonzalez-Juanatey, C.; Llorca, J.; Miranda-Filloy, J.A.; Amigo-Diaz, E.; Testa, A.;

Garcia-Porrua, C.; Martin, J.; Gonzalez-Gay, M.A. Endothelial dysfunction in psoriatic arthritis

patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors.

Arthritis Rheum. 2007, 57, 287–293.

67. Bodnar, N.; Kerekes, G.; Seres, I.; Paragh, G.; Kappelmayer, J.; Nemethne, Z.G.; Szegedi, G.;

Shoenfeld, Y.; Sipka, S.; Soltesz, P.; et al. Assessment of subclinical vascular disease associated

with ankylosing spondylitis. J. Rheumatol. 2011, 38, 723–729.

68. Wendling, D.; Racadot, E.; Auge, B.; Toussirot, E. Soluble intercellular adhesion molecule 1 in

spondylarthropathies. Clin. Rheumatol. 1998, 17, 202–204.

69. Sari, I.; Alacacioglu, A.; Kebapcilar, L.; Taylan, A.; Bilgir, O.; Yildiz, Y.; Yuksel, A.; Kozaci, D.L.

Assessment of soluble cell adhesion molecules and soluble CD40 ligand levels in ankylosing

spondylitis. Jt. Bone Spine 2010, 77, 85–87.

70. Kemeny-Beke, A.; Gesztelyi, R.; Bodnar, N.; Zsuga, J.; Kerekes, G.; Zsuga, M.; Biri, B.; Keki, S.;

Szodoray, P.; Berta, A.; et al. Increased production of asymmetric dimethylarginine (ADMA) in

ankylosing spondylitis: association with other clinical and laboratory parameters. Jt. Bone Spine

2011, 78, 184–187.

71. Erre, G.L.; Sanna, P.; Zinellu, A.; Ponchietti, A.; Fenu, P.; Sotgia, S.; Carru, C.; Ganau, A.;

Passiu, G. Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in

ankylosing spondylitis: A cross-sectional study. Clin. Rheumatol. 2011, 30, 21–27.

72. Brezinski, E.A.; Follansbee, M.R.; Armstrong, E.J.; Armstrong, A.W. Endothelial dysfunction

and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: A

systematic review. Curr. Pharm. Des. 2014, 20, 513–528.

73. Balci, D.D.; Balci, A.; Karazincir, S.; Ucar, E.; Iyigun, U.; Yalcin, F.; Seyfeli, E.; Inandi, T.;

Egilmez, E. Increased carotid artery intima-media thickness and impaired endothelial function in

psoriasis. J. Eur. Acad. Dermatol. Venereol. 2009, 23, 1–6.

74. Usta, M.; Yurdakul, S.; Aral, H.; Turan, E.; Oner, E.; Inal, B.B.; Oner, F.A.; Gurel, M.S.;

Guvenen, G. Vascular endothelial function assessed by a noninvasive ultrasound method and

serum asymmetric dimethylarginine concentrations in mild-to-moderate plaque-type psoriatic

patients. Clin. Biochem. 2011, 44, 1080–1084.

75. Martyn-Simmons, C.L.; Ranawaka, R.R.; Chowienczyk, P.; Crook, M.A.; Marber, M.S.;

Smith, C.H.; Barker, J.N. A prospective case-controlled cohort study of endothelial function in

patients with moderate to severe psoriasis. Br. J. Dermatol. 2011, 164, 26–32.

76. Hatoum, O.A.; Binion, D.G.; Otterson, M.F.; Gutterman, D.D. Acquired microvascular

dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation.

Gastroenterology 2003, 125, 58–69.

Int. J. Mol. Sci. 2014, 15 11345

77. Kocaman, O.; Sahin, T.; Aygun, C.; Senturk, O.; Hulagu, S. Endothelial dysfunction in patients

with ulcerative colitis. Inflamm. Bowel Dis. 2006, 12, 166–171.

78. Principi, M.; Mastrolonardo, M.; Scicchitano, P.; Gesualdo, M.; Sassara, M.; Guida, P.; Bucci, A.;

Zito, A.; Caputo, P.; Albano, F.; et al. Endothelial function and cardiovascular risk in active

inflammatory bowel diseases. J. Crohns Colitis 2013, 7, e427–e433.

79. Aloi, M.; Tromba, L.; di Nardo, G.; Dilillo, A.; del Giudice, E.; Marocchi, E.; Viola, F.; Civitelli, F.;

Berni, A.; Cucchiara, S. Premature subclinical atherosclerosis in pediatric inflammatory bowel

disease. J. Pediatr. 2012, 161, 589–594 e581.

80. Brand, D.D.; Latham, K.A.; Rosloniec, E.F. Collagen-induced arthritis. Nat. Protoc. 2007, 2,

1269–1275.

81. He, M.; Liang, X.; He, L.; Wen, W.; Zhao, S.; Wen, L.; Liu, Y.; Shyy, J.Y.; Yuan, Z. Endothelial

dysfunction in rheumatoid arthritis: The role of monocyte chemotactic protein-1-induced protein.

Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1384–1391.

82. Denys, A.; Clavel, G.; Semerano, L.; Lemeiter, D.; Boissier, M.C. A1.6 Vascular adhesion

molecule VCAM-1 overexpression in collagen induced arthritis: A model for rheumatoid

arthritis vascular dysfunction. Ann. Rheum. Dis. 2014, 73, A3.

83. Haruna, Y.; Morita, Y.; Komai, N.; Yada, T.; Sakuta, T.; Tomita, N.; Fox, D.A.; Kashihara, N.

Endothelial dysfunction in rat adjuvant-induced arthritis: Vascular superoxide production by

NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase. Arthritis Rheum. 2006, 54,

1847–1855.

84. Fang, Z.Y.; Fontaine, J.; Unger, P.; Berkenboom, G. Alterations of the endothelial function of

isolated aortae in rats with adjuvant arthritis. Arch. Int. Pharmacodyn. Ther. 1991, 311, 122–130.

85. Dooley, L.M.; Washington, E.A.; Abdalmula, A.; Tudor, E.M.; Kimpton, W.G.; Bailey, S.R.

Endothelial dysfunction in an ovine model of collagen-induced arthritis. J. Vasc. Res. 2014, 51,

90–101.

86. Neumann, P.; Gertzberg, N.; Johnson, A. TNF-alpha induces a decrease in eNOS promoter

activity. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286, L452–L459.

87. Kleinbongard, P.; Heusch, G.; Schulz, R. TNFalpha in atherosclerosis, myocardial

ischemia/reperfusion and heart failure. Pharmacol. Ther. 2010, 127, 295–314.

88. Rajan, S.; Ye, J.; Bai, S.; Huang, F.; Guo, Y.L. NF-kappaB, but not p38 MAP kinase, is required

for TNF-alpha-induced expression of cell adhesion molecules in endothelial cells. J. Cell. Biochem.

2008, 105, 477–486.

89. Bergh, N.; Ulfhammer, E.; Glise, K.; Jern, S.; Karlsson, L. Influence of TNF-alpha and

biomechanical stress on endothelial anti- and prothrombotic genes. Biochem. Biophys. Res. Commun.

2009, 385, 314–318.

90. Wang, P.; Ba, Z.F.; Chaudry, I.H. Administration of tumor necrosis factor-alpha in vivo

depresses endothelium-dependent relaxation. Am. J. Physiol. 1994, 266, H2535–H2541.

91. Chia, S.; Qadan, M.; Newton, R.; Ludlam, C.A.; Fox, K.A.; Newby, D.E. Intra-arterial tumor

necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue

plasminogen activator release in humans. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 695–701.

Int. J. Mol. Sci. 2014, 15 11346

92. Hingorani, A.D.; Cross, J.; Kharbanda, R.K.; Mullen, M.J.; Bhagat, K.; Taylor, M.; Donald, A.E.;

Palacios, M.; Griffin, G.E.; Deanfield, J.E.; et al. Acute systemic inflammation impairs

endothelium-dependent dilatation in humans. Circulation 2000, 102, 994–999.

93. Ohta, H.; Wada, H.; Niwa, T.; Kirii, H.; Iwamoto, N.; Fujii, H.; Saito, K.; Sekikawa, K.;

Seishima, M. Disruption of tumor necrosis factor-alpha gene diminishes the development of

atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005, 180, 11–17.

94. Kundu, S.; Ghosh, P.; Datta, S.; Ghosh, A.; Chattopadhyay, S.; Chatterjee, M. Oxidative stress as

a potential biomarker for determining disease activity in patients with rheumatoid arthritis.

Free Radic. Res. 2012, 46, 1482–1489.

95. Picchi, A.; Gao, X.; Belmadani, S.; Potter, B.J.; Focardi, M.; Chilian, W.M.; Zhang, C. Tumor

necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome.

Circ. Res. 2006, 99, 69–77.

96. Kalinowski, L.; Malinski, T. Endothelial NADH/NADPH-dependent enzymatic sources of

superoxide production: Relationship to endothelial dysfunction. Acta Biochim. Pol. 2004, 51,

459–469.

97. Gielis, J.F.; Lin, J.Y.; Wingler, K.; van Schil, P.E.; Schmidt, H.H.; Moens, A.L. Pathogenetic

role of eNOS uncoupling in cardiopulmonary disorders. Free Radic. Biol. Med. 2011, 50,

765–776.

98. Hamilton, C.A.; Miller, W.H.; Al-Benna, S.; Brosnan, M.J.; Drummond, R.D.; McBride, M.W.;

Dominiczak, A.F. Strategies to reduce oxidative stress in cardiovascular disease. Clin. Sci. (Lond.)

2004, 106, 219–234.

99. Wolin, M.S. Interactions of oxidants with vascular signaling Systems. Arterioscler. Thromb.

Vasc. Biol. 2000, 20, 1430–1442.

100. Biniecka, M.; Kennedy, A.; Ng, C.T.; Chang, T.C.; Balogh, E.; Fox, E.; Veale, D.J.; Fearon, U.;

O’Sullivan, J.N. Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative

stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis. Arthritis Res. Ther.

2011, 13, R121.

101. Ku, I.A.; Imboden, J.B.; Hsue, P.Y.; Ganz, P. Rheumatoid arthritis: Model of systemic

inflammation driving atherosclerosis. Circ. J. 2009, 73, 977–985.

102. Hurt-Camejo, E.; Paredes, S.; Masana, L.; Camejo, G.; Sartipy, P.; Rosengren, B.; Pedreno, J.;

Vallve, J.C.; Benito, P.; Wiklund, O. Elevated levels of small, low-density lipoprotein with high

affinity for arterial matrix components in patients with rheumatoid arthritis: Possible contribution

of phospholipase A2 to this atherogenic profile. Arthritis Rheum. 2001, 44, 2761–2767.

103. Norata, G.D.; Tonti, L.; Roma, P.; Catapano, A.L. Apoptosis and proliferation of endothelial

cells in early atherosclerotic lesions: possible role of oxidised LDL. Nutr. Metab. Cardiovasc. Dis.

2002, 12, 297–305.

104. Vladimirova-Kitova, L.; Deneva, T.; Angelova, E.; Nikolov, F.; Marinov, B.; Mateva, N.

Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with

newly detected severe hypercholesterolemia. Clin. Physiol. Funct. Imaging 2008, 28, 417–425.

105. Stancu, C.S.; Toma, L.; Sima, A.V. Dual role of lipoproteins in endothelial cell dysfunction in

atherosclerosis. Cell. Tissue Res. 2012, 349, 433–446.

Int. J. Mol. Sci. 2014, 15 11347

106. Narshi, C.B.; Giles, I.P.; Rahman, A. The endothelium: an interface between autoimmunity and

atherosclerosis in systemic lupus erythematosus? Lupus 2011, 20, 5–13.

107. Cieslik, P.; Hrycek, A.; Klucinski, P. Vasculopathy and vasculitis in systemic lupus

erythematosus. Pol. Arch. Med. Wewn. 2008, 118, 57–63.

108. Gomez-Zumaquero, J.M.; Tinahones, F.J.; de Ramon, E.; Camps, M.; Garrido, L.; Soriguer, F.J.

Association of biological markers of activity of systemic lupus erythematosus with levels of

anti-oxidized low-density lipoprotein antibodies. Rheumatology (Oxford) 2004, 43, 510–513.

109. Charakida, M.; Besler, C.; Batuca, J.R.; Sangle, S.; Marques, S.; Sousa, M.; Wang, G.;

Tousoulis, D.; Delgado Alves, J.; Loukogeorgakis, S.P.; et al. Vascular abnormalities,

paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA

2009, 302, 1210–1217.

110. Hjeltnes, G.; Hollan, I.; Forre, O.; Wiik, A.; Lyberg, T.; Mikkelsen, K.; Agewall, S. Endothelial

function improves within 6 weeks of treatment with methotrexate or methotrexate in combination

with a TNF-alpha inhibitor in rheumatoid arthritis patients. Scand. J. Rheumatol. 2012, 41,

240–242.

111. Cardillo, C.; Schinzari, F.; Mores, N.; Mettimano, M.; Melina, D.; Zoli, A.; Ferraccioli, G.

Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in

rheumatoid arthritis. Clin. Pharmacol. Ther. 2006, 80, 275–281.

112. Bilsborough, W.; Keen, H.; Taylor, A.; O’Driscoll, G.J.; Arnolda, L.; Green, D.J. Anti-tumour

necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults

with rheumatoid arthritis. Rheumatol. Int. 2006, 26, 1125–1131.

113. Hurlimann, D. Anti-tumor necrosis factor-alpha treatment improves endothelial function in

patients with rheumatoid arthritis. Circulation 2002, 106, 2184–2187.

114. Gonzalez-Juanatey, C.; Testa, A.; Garcia-Castelo, A.; Garcia-Porrua, C.; Llorca, J.;

Gonzalez-Gay, M.A. Active but transient improvement of endothelial function in rheumatoid

arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody.

Arthritis Rheum. 2004, 51, 447–450.

115. Sidiropoulos, P.I.; Siakka, P.; Pagonidis, K.; Raptopoulou, A.; Kritikos, H.; Tsetis, D.;

Boumpas, D.T. Sustained improvement of vascular endothelial function during anti-TNFalpha

treatment in rheumatoid arthritis patients. Scand. J. Rheumatol. 2009, 38, 6–10.

116. Bosello, S.; Santoliquido, A.; Zoli, A.; di Campli, C.; Flore, R.; Tondi, P.; Ferraccioli, G.

TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in

patients with long-standing severe rheumatoid arthritis. Clin. Rheumatol. 2008, 27, 833–839.

117. Komai, N.; Morita, Y.; Sakuta, T.; Kuwabara, A.; Kashihara, N. Anti-tumor necrosis factor

therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in

patients with rheumatoid arthritis. Mod. Rheumatol. 2007, 17, 385–390.

118. Van Eijk, I.C.; Peters, M.J.; Serne, E.H.; van der Horst-Bruinsma, I.E.; Dijkmans, B.A.;

Smulders, Y.M.; Nurmohamed, M.T. Microvascular function is impaired in ankylosing

spondylitis and improves after tumour necrosis factor alpha blockade. Ann. Rheum. Dis. 2009,

68, 362–366.

119. Syngle, A.; Vohra, K.; Sharma, A.; Kaur, L. Endothelial dysfunction in ankylosing spondylitis

improves after tumor necrosis factor-alpha blockade. Clin. Rheumatol. 2010, 29, 763–770.

Int. J. Mol. Sci. 2014, 15 11348

120. Avgerinou, G.; Tousoulis, D.; Siasos, G.; Oikonomou, E.; Maniatis, K.; Papageorgiou, N.;

Paraskevopoulos, T.; Miliou, A.; Koumaki, D.; Latsios, G.; et al. Anti-tumor necrosis factor

alpha treatment with adalimumab improves significantly endothelial function and decreases

inflammatory process in patients with chronic psoriasis. Int. J. Cardiol. 2011, 151, 382–383.

121. Schinzari, F.; Armuzzi, A.; de Pascalis, B.; Mores, N.; Tesauro, M.; Melina, D.; Cardillo, C.

Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with

Crohn’s disease. Clin. Pharmacol. Ther. 2008, 83, 70–76.

122. Galarraga, B.; Belch, J.J.; Pullar, T.; Ogston, S.; Khan, F. Clinical improvement in rheumatoid

arthritis is associated with healthier microvascular function in patients who respond to

antirheumatic therapy. J. Rheumatol. 2010, 37, 521–528.

123. Kerekes, G.; Soltesz, P.; Der, H.; Veres, K.; Szabo, Z.; Vegvari, A.; Szegedi, G.; Shoenfeld, Y.;

Szekanecz, Z. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis,

and lipid profile in rheumatoid arthritis. Clin. Rheumatol. 2009, 28, 705–710.

124. Veselinovic, M.V.; Zivkovic, V.I.; Toncev, S.; Tasic, N.; Bogdanovic, V.; Djuric, D.M.;

Jakovljevic, V. Carotid artery intima-media thickness and brachial artery flow-mediated

vasodilatation in patients with rheumatoid arthritis. VASA 2012, 41, 343–351.

125. Hafstrom, I.; Rohani, M.; Deneberg, S.; Wornert, M.; Jogestrand, T.; Frostegard, J. Effects of

low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for

atherosclerosis in patients with rheumatoid arthritis--a randomized study. J. Rheumatol. 2007, 34,

1810–1816.

126. Maki-Petaja, K.M.; Booth, A.D.; Hall, F.C.; Wallace, S.M.; Brown, J.; McEniery, C.M.;

Wilkinson, I.B. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic

stiffness and improve endothelial function in rheumatoid arthritis. J. Am. Coll. Cardiol. 2007, 50,

852–858.

127. Tikiz, C.; Utuk, O.; Pirildar, T.; Bayturan, O.; Bayindir, P.; Taneli, F.; Tikiz, H.; Tuzun, C.

Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory

markers and endothelial functions in patients with longterm rheumatoid arthritis. J. Rheumatol.

2005, 32, 2095–2101.

128. Hermann, F.; Forster, A.; Chenevard, R.; Enseleit, F.; Hurlimann, D.; Corti, R.; Spieker, L.E.;

Frey, D.; Hermann, M.; Riesen, W.; et al. Simvastatin improves endothelial function in patients

with rheumatoid arthritis. J. Am. Coll. Cardiol. 2005, 45, 461–464.

129. Ferreira, G.A.; Navarro, T.P.; Telles, R.W.; Andrade, L.E.; Sato, E.I. Atorvastatin therapy

improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: An

8 weeks controlled trial. Rheumatology (Oxford) 2007, 46, 1560–1565.

130. Klimiuk, P.A.; Sierakowski, S.; Domyslawska, I.; Chwiecko, J. Effect of etanercept on serum

levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular

endothelial growth factor in patients with rheumatoid arthritis. Scand. J. Rheumatol. 2009, 38,

439–444.

131. Gonzalez-Gay, M.A.; Garcia-Unzueta, M.T.; de Matias, J.M.; Gonzalez-Juanatey, C.;

Garcia-Porrua, C.; Sanchez-Andrade, A.; Martin, J.; Llorca, J. Influence of anti-TNF-alpha

infliximab therapy on adhesion molecules associated with atherogenesis in patients with

rheumatoid arthritis. Clin. Exp. Rheumatol. 2006, 24, 373–379.

Int. J. Mol. Sci. 2014, 15 11349

132. Ruyssen-Witrand, A.; Fautrel, B.; Saraux, A.; Le Loet, X.; Pham, T. Cardiovascular risk induced

by low-dose corticosteroids in rheumatoid arthritis: A systematic literature review. Jt. Bone Spine

2011, 78, 23–30.

133. Roman, M.J.; Shanker, B.A.; Davis, A.; Lockshin, M.D.; Sammaritano, L.; Simantov, R.;

Crow, M.K.; Schwartz, J.E.; Paget, S.A.; Devereux, R.B.; et al. Prevalence and correlates of

accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 2003, 349,

2399–2406.

134. Palinski, W. Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler. Thromb.

Vasc. Biol. 2002, 22, 1745–1750.

135. Kanda, H.; Hamasaki, K.; Kubo, K.; Tateishi, S.; Yonezumi, A.; Kanda, Y.; Yamamoto, K.;

Mimura, T. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis.

J. Rheumatol. 2002, 29, 2024–2026.

136. McCarey, D.W.; McInnes, I.B.; Madhok, R.; Hampson, R.; Scherbakova, O.; Ford, I.; Capell, H.A.;

Sattar, N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): Double-blind, randomised

placebo-controlled trial. Lancet 2004, 363, 2015–2021.

137. Okamoto, H.; Koizumi, K.; Kamitsuji, S.; Inoue, E.; Hara, M.; Tomatsu, T.; Kamatani, N.;

Yamanaka, H. Beneficial action of statins in patients with rheumatoid arthritis in a large

observational cohort. J. Rheumatol. 2007, 34, 964–968.

138. Sheng, X.; Murphy, M.J.; Macdonald, T.M.; Wei, L. Effectiveness of statins on total cholesterol

and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis.

J. Rheumatol. 2012, 39, 32–40.

139. Semb, A.G.; Kvien, T.K.; DeMicco, D.A.; Fayyad, R.; Wun, C.C.; LaRosa, J.C.; Betteridge, J.;

Pedersen, T.R.; Holme, I. Effect of intensive lipid-lowering therapy on cardiovascular outcome

in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012, 64,

2836–2846.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/)